Human Insulin-like Growth Factor II
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
| Amount : | 100 µg |
| Purification : | Reducing and Non-Reducing SDS PAGE at >= 95% |
| Content : | Lyophilized from a sterile (0.2 micron) filtered aqueous solution containing 0.1% Trifluoroacetic Acid (TFA) Sterile water at 0.1 mg/mL |
| Storage condition : | Store at -20°C |
| AA sequence : | AYRPSETLCG GELVDTLQFV CGDRGFYFSR PASRVSRRSR GIVEECCFRS CDLALLETYC ATPAKSE |
Source: Genetically modified E.coli.
Predicted MW: Monomer, 7.5 kDa (67 aa)
Insulin-like growth factor II (IGF-II) is an important fetal growth hormone made by theca cells during gestation. IGF-II engages the IGF-I receptor (IGF1R) to mediate embryonic growth. IGF-II also binds the sink IGF-II receptor (IGF2R) leading to IGF-II degradation.
Endotoxin: Less than 0.1 ng/µg (1 IEU/µg) as determined by LAL test.
Biological Activity was determined by FDC-P1 cell proliferation at <=15 ng/mL; >= 6.7 x 10^4 units/mg (typical ED50 is 1-10 ng/mL). Centrifuge vial before opening, Suspend the product by gently pipetting the above recommended solution down the sides of the vial. DO NOT VORTEX. Allow several minutes for complete reconstitution. For prolonged storage, dilute to working aliquots in a 0.1% BSA solution, store at -80°C and avoid repeat freeze thaws. Upon reconstitution, a small amount of visible precipitate can be expected. A 10% overfill has been added to the total material vialed to compensate for this loss.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
| Subcellular location: | Secreted |
| Post transnational modification: | Proteolytically processed by PCSK4, proIGF2 is cleaved at Arg-128 and Arg-92 to generate big-IGF2 and mature IGF2. |
| Tissue Specificity: | Expressed in heart, placenta, lung, liver, muscle, kidney, tongue, limb, eye and pancreas. |
| BioGrid: | 109702. 29 interactions. |
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
